Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$36.81 USD

36.81
4,382,622

-0.45 (-1.21%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $36.84 +0.03 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study

by Zacks Equity Research

Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.

Zacks Equity Research

Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

by Zacks Equity Research

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

Zacks Equity Research

Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study

by Zacks Equity Research

Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.

Zacks Equity Research

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

by Zacks Equity Research

Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.

Zacks Equity Research

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 55.00% and 18.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q3 results.

Zacks Equity Research

Earnings Preview: Exelixis (EXEL) Q3 Earnings Expected to Decline

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

by Zacks Equity Research

Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

Zacks Equity Research

Seattle Genetics Up on Positive Data From Bladder Cancer Study

by Zacks Equity Research

Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.

Zacks Equity Research

Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC

by Zacks Equity Research

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.

Ekta Bagri headshot

Renal Cell Carcinoma Space in Focus: Some Key Developments

by Ekta Bagri

The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.

Zacks Equity Research

Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

by Zacks Equity Research

Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.

Zacks Equity Research

Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.

Zacks Equity Research

Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 8.70% and 5.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

Zacks Equity Research

Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

EXEL or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

by Zacks Equity Research

Key highlights of the past week include collaborations and other pipeline updates.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 17th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Zacks Equity Research

Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study

by Zacks Equity Research

Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.

Zacks Equity Research

Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Swarup Gupta headshot

Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

by Swarup Gupta

The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

Zacks Equity Research

Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

by Zacks Equity Research

Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.